← Back to Overview To Chemical Defense →

Note for contributors: This document is a living research effort. We welcome feedback and discussion!

Policy

From Reactive Regulation to Proactive Incentives

Rotation Opportunity
Incentivize preventive and pre-clinical interventions to "engineer resilience" against chronic disease.
Key Insight
20th century environmental policies delivered 30:1 returns, but regulatory momentum has stalled since the 1990s.

Despite mounting evidence of environmental factors contributing to disease, there has been fairly little regulatory action against industrial chemicals in the U.S. since the high-water mark of the 1970s–1990s.

For much of the twentieth century, exposure science was tethered to policy, delivering enormous returns: the Clean Air Act generated benefit-to-cost ratios exceeding 30:1,[2] leaded gasoline phase-out returned $17–$200 per dollar invested,[1] and the Montreal Protocol prevented millions of cancer cases.[3]

Key wins: PCB & DDT phase-outs cut dietary DDT from 13.8 to 1.88 mg/day.[4] Leaded gasoline phase-out dropped blood lead from 17.1 to 2.7 µg/dL.[5] These prove the model works—but the pipeline has stalled.

Key Insight
Place-based investments, tort settlement reinvestment, and TERP translation pathways can create sustainable funding for prevention R&D.

The FDA focuses on established disease, offering no fast tracks for prophylactic medications or early biomarker trials—leaving preventive interventions without clear regulatory pathways.

Three funding mechanisms could unlock this:

  • Place-based investments targeting high-exposure communities
  • Toxic-tort settlement reinvestment into dedicated R&D funds
  • Public-private partnerships modeled on BARDA's advance market commitments
Key Insight
A prevention-oriented regulatory framework would create new market categories and reduce the $4.6T annual burden of environmentally-mediated disease.

If even a fraction of the 30:1 returns from 20th century environmental policy can be replicated through proactive therapeutic incentives, the economic case is overwhelming. A 'Resilience Fast Track' at FDA could do for environmental prevention what breakthrough therapy designation did for rare diseases.

  1. Grosse SD, et al. Economic gains resulting from the reduction in children's exposure to lead in the United States. Environ Health Perspect. 2002. PubMed
  2. US EPA. Benefits and costs of the Clean Air Act 1990-2020: Second Prospective Study. EPA Report. 2011. EPA
  3. US EPA. Updating ozone calculations and emissions profiles for use in the Atmospheric and Health Effects Framework model. EPA Report. 2020. EPA
  4. ATSDR. Toxicological profile for DDT, DDE, and DDD. Agency for Toxic Substances and Disease Registry. 2002. ATSDR
  5. CDC. Blood lead levels in children aged 1-5 years — United States, 1999-2010. MMWR. 2013. CDC

Full White Paper Coming Soon

Be notified when the complete Four Rotations thesis is released.

Subscribe to Our Newsletter